ACOR:NSD-Acorda Therapeutics Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.61

Change

-0.01 (-1.61)%

Market Cap

USD 0.02B

Volume

0.05M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ACOR Stock Forecast & Price:
Based on the Acorda Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Acorda Therapeutics Inc is not available over the next 12 months. Acorda Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Acorda Therapeutics Inc is Bearish, which is based on 2 positive signals and 8 negative signals. At the last closing, Acorda Therapeutics Inc’s stock price was USD 0.61. Acorda Therapeutics Inc’s stock price has changed by -4.39% over the past week, +15.09% over the past month and -80.26% over the last year.

About Acorda Therapeutics Inc (ACOR:NSD)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD PPD Inc

N/A

USD16.61B 47.04 21.58
VTRS Viatris Inc

+0.12 (+1.09%)

USD13.36B 16.70 7.05
NBIX Neurocrine Biosciences Inc

+3.18 (+2.67%)

USD11.44B 195.03 99.45
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intracellular Th

+1.04 (+2.03%)

USD4.85B N/A -14.08
ALKS Alkermes Plc

-0.07 (-0.29%)

USD4.03B N/A -67.27
LNTH Lantheus Holdings Inc

-0.31 (-0.53%)

USD3.96B 37.58 17.91
EVO Evotec SE ADR

+0.31 (+3.62%)

USD3.13B 428.50 -18.98

ETFs Containing ACOR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -74.48% 36% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.48% 36% F 18% F
Trailing 12 Months  
Capital Gain -78.67% 34% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.67% 34% F 17% F
Trailing 5 Years  
Capital Gain -99.50% 6% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.50% 6% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -58.86% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.86% 1% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.49% 64% D 47% F
Risk Adjusted Return -170.65% 2% F N/A N/A
Market Capitalization 0.02B 19% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.11 90% A- 93% A
Price/Book Ratio 0.18 98% A+ 98% A+
Price / Cash Flow Ratio -0.36 36% F 44% F
EV/EBITDA -14.77 87% B+ 85% B
Management Effectiveness  
Return on Equity -87.93% 35% F 19% F
Return on Invested Capital -18.42% 56% F 36% F
Return on Assets -6.52% 59% F 39% F
Debt to Equity Ratio 118.22% 27% F 18% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.15 100% A+ 91% A-
Short Percent 6.09% 33% F 26% F
Beta 1.66 21% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector